Chardan Capital analyst Keay Nakae has reiterated their bullish stance on FEMY stock, giving a Buy rating yesterday.
Keay Nakae of Chardan Capital has given a Buy rating to Femasys stock (FEMY) due to a combination of factors.
Firstly, the company demonstrated promising financial results in its 3Q23 report and has sufficient cash to support operations for at least a year. The company has raised substantial funds through share sales and exercising of common warrants.
Secondly, Femasys is making significant strides in its clinical operations. The company’s FINALE trial of FemBloc, a non-surgical permanent birth control treatment, has begun its first-patient-in phase. The trial has been designed with a robust methodology that includes an interim analysis of clinical data endpoints. Nakae believes that this could lead to FDA approval and a potential U.S. commercial launch in the second half of 2026.
Moreover, Femasys has also received a Notice of Allowance for a new U.S. patent application for FemBloc, providing further validation of the company’s innovative approach.
In another report released yesterday, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Femasys (FEMY) Company Description:
Femasys Inc is a biomedical company focused on transforming women’s healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. Its mission is to provide women with minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
Read More on FEMY:
- Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
- Femasys completes EU MDR final audit
- Femasys Inc. EU MDR Final Audit Successfully Completed
- Femasys to showcase FemBloc, other products at AAGL meeting
- Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
